Press releases, news & announcements

Prioritising profitability over sales volumes has supported our margins, which improved sequentially into the first quarter.”

Following the Offering Circular published on 22 November 2022, DSM and DSM-Firmenich are required to announce transactions in relation to the ordinary shares in their respective share capital in accordance with the Dutch public offer rules.

Following the Offering Circular published on 22 November 2022, DSM and DSM-Firmenich are required to announce transactions in relation to the ordinary shares in their respective share capital in accordance with the Dutch public offer rules.

Following the Offering Circular published on 22 November 2022, DSM and DSM-Firmenich are required to announce transactions in relation to the ordinary shares in their respective share capital in accordance with the Dutch public offer rules.

Following the Offering Circular published on 22 November 2022, DSM and DSM-Firmenich are required to announce transactions in relation to the ordinary shares in their respective share capital in accordance with the Dutch public offer rules.

Following the Offering Circular published on 22 November 2022, DSM and DSM-Firmenich are required to announce transactions in relation to the ordinary shares in their respective share capital in accordance with the Dutch public offer rules.

Following the Offering Circular published on 22 November 2022, DSM and DSM-Firmenich are required to announce transactions in relation to the ordinary shares in their respective share capital in accordance with the Dutch public offer rules.

Following the Offering Circular published on 22 November 2022, DSM and DSM-Firmenich are required to announce transactions in relation to the ordinary shares in their respective share capital in accordance with the Dutch public offer rules.

DSM announces that it has entered into exclusive negotiations with Adare Pharma Solutions in order to acquire Adare Biome, a pioneer in the development and manufacturing of postbiotics, for an enterprise value of €275 million. This transaction represents an estimated 2023 EV/EBITDA multiple of 18x.

Following the Offering Circular published on 22 November 2022, Royal DSM is required to announce transactions relating to the ordinary shares in its capital in accordance with the Dutch public offer rules. This includes the delivery of treasury shares to employees in view of settling the vesting of share units or the exercise of stock options.

Following the Offering Circular published on 22 November 2022, Royal DSM is required to announce transactions relating to the ordinary shares in its capital in accordance with the Dutch public offer rules. This includes the delivery of treasury shares to employees in view of settling the vesting of share units or the exercise of stock options.

Following the Offering Circular published on 22 November 2022, Royal DSM is required to announce transactions relating to the ordinary shares in its capital in accordance with the Dutch public offer rules. This includes the delivery of treasury shares to employees in view of settling the vesting of share units or the exercise of stock options.

Following the Offering Circular published on 22 November 2022, Royal DSM is required to announce transactions relating to the ordinary shares in its capital in accordance with the Dutch public offer rules. This includes the delivery of treasury shares to employees in view of settling the vesting of share units or the exercise of stock options.

Royal DSM announces the completion of the sale of its Engineering Materials business to Advent International and LANXESS for an Enterprise Value of €3.85 billion.

Following the Offering Circular published on 22 November 2022, Royal DSM is required to announce transactions relating to the ordinary shares in its capital in accordance with the Dutch public offer rules. This includes the delivery of treasury shares to employees in view of settling the vesting of share units or the exercise of stock options.

Following the Offering Circular published on 22 November 2022, Royal DSM is required to announce transactions relating to the ordinary shares in its capital in accordance with the Dutch public offer rules. This includes the delivery of treasury shares to employees in view of settling the vesting of share units or the exercise of stock options.

Dutch dairy company Royal FrieslandCampina, DSM, and feed supplier Agrifirm have successfully incorporated Bovaer® into the regular farming activities of 158 dairy farms in the Netherlands in the world’s first large-scale on-farm use of the methane-reducing feed additive for cattle.

Following the Offering Circular published on 22 November 2022, Royal DSM is required to announce transactions relating to the ordinary shares in its capital in accordance with the Dutch public offer rules. This includes the delivery of treasury shares to employees in view of settling the vesting of share units or the exercise of stock options.

DSM reveals the first audited results of its progress in helping to address urgent societal and environmental challenges linked to how the world produces and consumes food.

Following the Offering Circular published on 22 November 2022, Royal DSM is required to announce transactions relating to the ordinary shares in its capital in accordance with the Dutch public offer rules. This includes the delivery of treasury shares to employees in view of settling the vesting of share units or the exercise of stock options.

Following the Offering Circular published on 22 November 2022, Royal DSM is required to announce transactions relating to the ordinary shares in its capital in accordance with the Dutch public offer rules. This includes the delivery of treasury shares to employees in view of settling the vesting of share units or the exercise of stock options.

Following the Offering Circular published on 22 November 2022, Royal DSM is required to announce transactions relating to the ordinary shares in its capital in accordance with the Dutch public offer rules. This includes the delivery of treasury shares to employees in view of settling the vesting of share units or the exercise of stock options.

Following the Offering Circular published on 22 November 2022, Royal DSM is required to announce transactions relating to the ordinary shares in its capital in accordance with the Dutch public offer rules. This includes the delivery of treasury shares to employees in view of settling the vesting of share units or the exercise of stock options.

Following the Offering Circular published on 22 November 2022, Royal DSM is required to announce transactions relating to the ordinary shares in its capital in accordance with the Dutch public offer rules. This includes the delivery of treasury shares to employees in view of settling the vesting of share units or the exercise of stock options.

Following the Offering Circular published on 22 November 2022, Royal DSM is required to announce transactions relating to the ordinary shares in its capital in accordance with the Dutch public offer rules. This includes the delivery of treasury shares to employees in view of settling the vesting of share units or the exercise of stock options.

Following the Offering Circular published on 22 November 2022, Royal DSM is required to announce transactions relating to the ordinary shares in its capital in accordance with the Dutch public offer rules. This includes the delivery of treasury shares to employees in view of settling the vesting of share units or the exercise of stock options.

Following the Offering Circular published on 22 November 2022, Royal DSM is required to announce transactions relating to the ordinary shares in its capital in accordance with the Dutch public offer rules. This includes the delivery of treasury shares to employees in view of settling the vesting of share units or the exercise of stock options.

Following the Offering Circular published on 22 November 2022, Royal DSM is required to announce transactions relating to the ordinary shares in its capital in accordance with the Dutch public offer rules. This includes the delivery of treasury shares to employees in view of settling the vesting of share units or the exercise of stock options.

Following the Offering Circular published on 22 November 2022, Royal DSM is required to announce transactions relating to the ordinary shares in its capital in accordance with the Dutch public offer rules. This includes the delivery of treasury shares to employees in view of settling the vesting of share units or the exercise of stock options.

Following the Offering Circular published on 22 November 2022, Royal DSM is required to announce transactions relating to the ordinary shares in its capital in accordance with the Dutch public offer rules. This includes the delivery of treasury shares to employees in view of settling the vesting of share units or the exercise of stock options.

Following the Offering Circular published on 22 November 2022, Royal DSM is required to announce transactions relating to the ordinary shares in its capital in accordance with the Dutch public offer rules. This includes the delivery of treasury shares to employees in view of settling the vesting of share units or the exercise of stock options.

Following the Offering Circular published on 22 November 2022, Royal DSM is required to announce transactions relating to the ordinary shares in its capital in accordance with the Dutch public offer rules. This includes the delivery of treasury shares to employees in view of settling the vesting of share units or the exercise of stock options.

Following the Offering Circular published on 22 November 2022, Royal DSM is required to announce transactions relating to the ordinary shares in its capital in accordance with the Dutch public offer rules. This includes the delivery of treasury shares to employees in view of settling the vesting of share units or the exercise of stock options.

Following the Offering Circular published on 22 November 2022, Royal DSM is required to announce transactions relating to the ordinary shares in its capital in accordance with the Dutch public offer rules. This includes the delivery of treasury shares to employees in view of settling the vesting of share units or the exercise of stock options.

Following the Offering Circular published on 22 November 2022, Royal DSM is required to announce transactions relating to the ordinary shares in its capital in accordance with the Dutch public offer rules. This includes the delivery of treasury shares to employees in view of settling the vesting of share units or the exercise of stock options.

Royal DSM, a global purpose-led, performance-driven leader in Health, Nutrition & Bioscience, today announces the publication of its 2022 Integrated Annual Report (IAR).

Following the Offering Circular published on 22 November 2022, Royal DSM is required to announce transactions relating to the ordinary shares in its capital in accordance with the Dutch public offer rules. This includes the delivery of treasury shares to employees in view of settling the vesting of share units or the exercise of stock options.

Following the Offering Circular published on 22 November 2022, Royal DSM is required to announce transactions relating to the ordinary shares in its capital in accordance with the Dutch public offer rules. This includes the delivery of treasury shares to employees in view of settling the vesting of share units or the exercise of stock options.

Following the Offering Circular published on 22 November 2022, Royal DSM is required to announce transactions relating to the ordinary shares in its capital in accordance with the Dutch public offer rules. This includes the delivery of treasury shares to employees in view of settling the vesting of share units or the exercise of stock options.

Following the Offering Circular published on 22 November 2022, Royal DSM is required to announce transactions relating to the ordinary shares in its capital in accordance with the Dutch public offer rules. This includes the delivery of treasury shares to employees in view of settling the vesting of share units or the exercise of stock options.

Following the Offering Circular published on 22 November 2022, Royal DSM is required to announce transactions relating to the ordinary shares in its capital in accordance with the Dutch public offer rules. This includes the delivery of treasury shares to employees in view of settling the vesting of share units or the exercise of stock options.

DSM delivered a solid performance in 2022 against a background of continued global supply chain challenges and significantly higher energy and raw materials costs, consolidating the strong growth of 2021. Pricing actions to counter higher costs, supported top-line growth, however with a price-cost gap impacting near-term margins, especially in Animal, Nutrition & Health.

Following the Offering Circular published on 22 November 2022, Royal DSM is required to announce transactions relating to the ordinary shares in its capital in accordance with the Dutch public offer rules. This includes the delivery of treasury shares to employees in view of settling the vesting of share units or the exercise of stock options.

Following the Offering Circular published on 22 November 2022, Royal DSM is required to announce transactions relating to the ordinary shares in its capital in accordance with the Dutch public offer rules. This includes the delivery of treasury shares to employees in view of settling the vesting of share units or the exercise of stock options.

Following the Offering Circular published on 22 November 2022, Royal DSM is required to announce transactions relating to the ordinary shares in its capital in accordance with the Dutch public offer rules. This includes the delivery of treasury shares to employees in view of settling the vesting of share units or the exercise of stock options.

Following the Offering Circular published on 22 November 2022, Royal DSM is required to announce transactions relating to the ordinary shares in its capital in accordance with the Dutch public offer rules. This includes the delivery of treasury shares to employees in view of settling the vesting of share units or the exercise of stock options.

Following the Offering Circular published on 22 November 2022, Royal DSM is required to announce transactions relating to the ordinary shares in its capital in accordance with the Dutch public offer rules. This includes the delivery of treasury shares to employees in view of settling the vesting of share units or the exercise of stock options.

Following the Offering Circular published on 22 November 2022, Royal DSM is required to announce transactions relating to the ordinary shares in its capital in accordance with the Dutch public offer rules. This includes the delivery of treasury shares to employees in view of settling the vesting of share units or the exercise of stock options.

Following the Offering Circular published on 22 November 2022, Royal DSM is required to announce transactions relating to the ordinary shares in its capital in accordance with the Dutch public offer rules. This includes the delivery of treasury shares to employees in view of settling the vesting of share units or the exercise of stock options.

Following the Offering Circular published on 22 November 2022, Royal DSM is required to announce transactions relating to the ordinary shares in its capital in accordance with the Dutch public offer rules. This includes the delivery of treasury shares to employees in view of settling the vesting of share units or the exercise of stock options.

Following the Offering Circular published on 22 November 2022, Royal DSM is required to announce transactions relating to the ordinary shares in its capital in accordance with the Dutch public offer rules. This includes the delivery of treasury shares to employees in view of settling the vesting of share units or the exercise of stock options.

DSM today held an Extraordinary General Meeting of Shareholders (EGM). The DSM Shareholders approved the proposed merger between DSM and Firmenich International SA (Firmenich) and voted in favour of all related resolutions as set out in the notice of the EGM.

Following the Offering Circular published on 22 November 2022, Royal DSM is required to announce transactions relating to the ordinary shares in its capital in accordance with the Dutch public offer rules. This includes the delivery of treasury shares to employees in view of settling the vesting of share units or the exercise of stock options.

Following the Offering Circular published on 22 November 2022, Royal DSM is required to announce transactions relating to the ordinary shares in its capital in accordance with the Dutch public offer rules. This includes the delivery of treasury shares to employees in view of settling the vesting of share units or the exercise of stock options.

Following the Offering Circular published on 22 November 2022, Royal DSM is required to announce transactions relating to the ordinary shares in its capital in accordance with the Dutch public offer rules. This includes the delivery of treasury shares to employees in view of settling the vesting of share units or the exercise of stock options.

Following the Offering Circular published on 22 November 2022, Royal DSM is required to announce transactions relating to the ordinary shares in its capital in accordance with the Dutch public offer rules. This includes the delivery of treasury shares to employees in view of settling the vesting of share units or the exercise of stock options.

Following the Offering Circular published on 22 November 2022, Royal DSM is required to announce transactions relating to the ordinary shares in its capital in accordance with the Dutch public offer rules. This includes the delivery of treasury shares to employees in view of settling the vesting of share units or the exercise of stock options.

Following the Offering Circular published on 22 November 2022, Royal DSM is required to announce transactions relating to the ordinary shares in its capital in accordance with the Dutch public offer rules. This includes the delivery of treasury shares to employees in view of settling the vesting of share units or the exercise of stock options.

Following the Offering Circular published on 22 November 2022, Royal DSM is required to announce transactions relating to the ordinary shares in its capital in accordance with the Dutch public offer rules. This includes the delivery of treasury shares to employees in view of settling the vesting of share units or the exercise of stock options.

Following the Offering Circular published on 22 November 2022, Royal DSM is required to announce transactions relating to the ordinary shares in its capital in accordance with the Dutch public offer rules. This includes the delivery of treasury shares to employees in view of settling the vesting of share units or the exercise of stock options.

Following the Offering Circular published on 22 November 2022, Royal DSM is required to announce transactions relating to the ordinary shares in its capital in accordance with the Dutch public offer rules. This includes the delivery of treasury shares to employees in view of settling the vesting of share units or the exercise of stock options.

Following the Offering Circular published on 22 November 2022, Royal DSM is required to announce transactions relating to the ordinary shares in its capital in accordance with the Dutch public offer rules. This includes the delivery of treasury shares to employees in view of settling the vesting of share units or the exercise of stock options.

Following the Offering Circular published on 22 November 2022, Royal DSM is required to announce transactions relating to the ordinary shares in its capital in accordance with the Dutch public offer rules. This includes the delivery of treasury shares to employees in view of settling the vesting of share units or the exercise of stock options.

Following the Offering Circular published on 22 November 2022, Royal DSM is required to announce transactions relating to the ordinary shares in its capital in accordance with the Dutch public offer rules. This includes the delivery of treasury shares to employees in view of settling the vesting of share units or the exercise of stock options.

Following the Offering Circular published on 22 November 2022, Royal DSM is required to announce transactions relating to the ordinary shares in its capital in accordance with the Dutch public offer rules. This includes the delivery of treasury shares to employees in view of settling the vesting of share units or the exercise of stock options.

Following the Offering Circular published on 22 November 2022, Royal DSM is required to announce transactions relating to the ordinary shares in its capital in accordance with the Dutch public offer rules. This includes the delivery of treasury shares to employees in view of settling the vesting of share units or the exercise of stock options.

Following the Offering Circular published on 22 November 2022, Royal DSM is required to announce transactions relating to the ordinary shares in its capital in accordance with the Dutch public offer rules. This includes the delivery of treasury shares to employees in view of settling the vesting of share units or the exercise of stock options.

Following the Offering Circular published on 22 November 2022, Royal DSM is required to announce transactions relating to the ordinary shares in its capital in accordance with the Dutch public offer rules. This includes the delivery of treasury shares to employees in view of settling the vesting of share units or the exercise of stock options.

Following the Offering Circular published on 22 November 2022, Royal DSM is required to announce transactions relating to the ordinary shares in its capital in accordance with the Dutch public offer rules. This includes the delivery of treasury shares to employees in view of settling the vesting of share units or the exercise of stock options.

Following the Offering Circular published on 22 November 2022, Royal DSM is required to announce transactions relating to the ordinary shares in its capital in accordance with the Dutch public offer rules. This includes the delivery of treasury shares to employees in view of settling the vesting of share units or the exercise of stock options.

Following the Offering Circular published on 22 November 2022, Royal DSM is required to announce transactions relating to the ordinary shares in its capital in accordance with the Dutch public offer rules. This includes the delivery of treasury shares to employees in view of settling the vesting of share units or the exercise of stock options.

Following the Offering Circular published on 22 November 2022, Royal DSM is required to announce transactions relating to the ordinary shares in its capital in accordance with the Dutch public offer rules. This includes the delivery of treasury shares to employees in view of settling the vesting of share units or the exercise of stock options.

Following the Offering Circular published on 22 November 2022, Royal DSM is required to announce transactions relating to the ordinary shares in its capital in accordance with the Dutch public offer rules. This includes the delivery of treasury shares to employees in view of settling the vesting of share units or the exercise of stock options.

Following the Offering Circular published on 22 November 2022, Royal DSM is required to announce transactions relating to the ordinary shares in its capital in accordance with the Dutch public offer rules. This includes the delivery of treasury shares to employees in view of settling the vesting of share units or the exercise of stock options.

Following the Offering Circular published on 22 November 2022, Royal DSM is required to announce transactions relating to the ordinary shares in its capital in accordance with the Dutch public offer rules.

Following the Offering Circular published on 22 November 2022, Royal DSM is required to announce transactions relating to the ordinary shares in its capital in accordance with the Dutch public offer rules.

The plant will significantly increase global production of Bovaer®, DSM’s unique methane-reducing feed additive for cattle. In an official groundbreaking ceremony attended by the First Minister of Scotland, Nicola Sturgeon, and Dimitri de Vreeze, Co-CEO of DSM, the company marked the next step in its plan to use Bovaer® to reduce global methane emissions and contribute to worldwide methane reduction targets.

DSM confirms that its target to cut scope 1 and 2 greenhouse gas (GHG) emissions has been determined to be in line with the latest climate science and in keeping global warming to no more than 1.5°C by the Science Based Targets initiative (SBTi).

DSM’s trading update for the first nine months of 2022 is out now and our Health, Nutrition & Bioscience businesses all delivered good sales growth. Market demand remained resilient in what is a challenging macro-economic environment with the rising cost inflation.

DSM today announces the completion of its acquisition of Prodap, a leading animal nutrition and technology company in Brazil.

DSM, a global purpose-led science-based company, today announces the completion of the sale of its Protective Materials business to Avient Corporation

A good half year performance underpinned by resilient market demand.

DSM announces that it pledges to purchase all of its electricity worldwide from renewable sources

Royal DSM, a global purpose-led science-based company, today provides the investment community with comparative quarterly figures for 2021 and 2022 Q1.

Royal DSM, a global purpose-led science-based company, announces it has reached an agreement to acquire Prodap, a Brazilian animal nutrition and technology company that combines technology offerings, consulting services, and customized nutritional solutions to drive efficiency and sustainability in animal farming.

Royal DSM, a global purpose-led science-based company, today announces that it has reached an agreement to sell its Engineering Materials business to Advent International and LANXESS for an Enterprise Value of €3.85 billion.

Royal DSM and the World Food Programme (WFP) have agreed to extend their partnership and scale up rice fortification worldwide for a further three years. The partnership will seek to improve the availability and accessibility of nutritious foods in order to reach vulnerable people where key dietary decisions are made.

Royal DSM, a global purpose-led science-based company, confirmed its resolution to declare a dividend for the financial year 2021 of €2.50 per ordinary share was passed today, 10 May 2022, at its Annual General Meeting of Shareholders.

Royal DSM, a global purpose-led science-based company, today held its Annual General Meeting of Shareholders. All the resolutions on the agenda were approved by the shareholders.

Royal DSM, a global purpose-led science-based company, the United Nations’ children’s agency UNICEF, and Swiss-based nutrition think tank and incubator Sight and Life have renewed their long-term partnership to deliver better nutrition for at-risk groups in countries in Sub-Saharan Africa and Asia.

Royal DSM, a global purpose-led science-based company, has repurchased 40,085 of its own shares in the period from 2 May 2022 up to and including 6 May 2022 at an average price of €156.08.

Royal DSM, a global purpose-led science-based company, has repurchased 157,671 of its own shares in the period from 25 April 2022 up to and including 29 April 2022 at an average price of €156.34.

DSM delivered a good first quarter.

Elanco Animal Health Incorporated (ELAN: NYSE) and Royal DSM have created a strategic alliance connecting two leading, sustainability-focused companies to address one of society’s most significant opportunities of the decade, mitigating climate change by reducing greenhouse gas emissions from farming. Elanco has secured the exclusive U.S. licensing rights to develop, manufacture and commercialize Bovaer® for beef and dairy cattle.

Royal DSM, a global purpose-led science-based company, has repurchased 142,403 of its own shares in the period from 18 April 2022 up to and including 22 April 2022 at an average price of €155.73.

European dairy cooperative Arla Foods and global purpose-led science-based company, Royal DSM, are set to start a large-scale on-farm pilot with the methane reducing feed additive Bovaer® on 10,000 dairy cows across three European countries.

Royal DSM, a global purpose-led science-based company, has repurchased 101,258 of its own shares in the period from 11 April 2022 up to and including 15 April 2022 at an average price of €158.07.

Royal DSM, a global purpose-led science-based company, today announces that it has reached an agreement to sell its Protective Materials business to Avient Corporation for an Enterprise Value of €1.44 billion.

Royal DSM, a global purpose-led science-based company, has repurchased 173,491 of its own shares in the period from 4 April 2022 up to and including 8 April 2022 at an average price of €162.36.

Royal DSM, a global purpose-led science-based company, has repurchased 171,521 of its own shares in the period from 28 March 2022 up to and including 1 April 2022 at an average price of €162.39.

Royal DSM, a global purpose-led science-based company, today provides preliminary comparative financial figures for 2021 following the establishment of DSM’s Health, Nutrition & Bioscience (“HNB”) structure, which became effective as of 1 January 2022.

Royal DSM, a global purpose-led science-based company, has repurchased 205,518 of its own shares in the period from 21 March 2022 up to and including 25 March 2022 at an average price of €160.28.

The Bovaer® pilot collaboration between the Dutch companies FrieslandCampina, DSM, and Agrifirm marks an important step forward in increasing the sustainability of the dairy sector. Some 200 FrieslandCampina dairy farms in the Netherlands will take part in the pilot in the second half of 2022. Providing the results are positive, the use of Bovaer® will be further upscaled from 2023.

Royal DSM, a global purpose-led science-based company, announces that European Union (EU) member states approved the marketing of the methane-reducing feed additive for dairy cows, Bovaer®, in the EU. After inclusion in the EU registry, expected in the coming weeks, it is the first time a feed additive authorised in the EU for environmental benefits can be marketed. This marks a significant milestone for DSM, paving the way for Bovaer® to revolutionize the dairy market.

Companies to produce highly sought-after molecules such as steviol glycosides Reb M and Reb D through fermentation.

Bain Capital completes acquisition of DSM Sinochem Pharmaceuticals from DSM and Sinochem, both of whom held an equity stake of 50%.

DSM anticipates receiving about €200 million in cash in various steps in 2018 and 2019.

Improving society’s ability to adapt to a changing climate.

Ertharin Cousin, former Executive Director of the United Nations World Food Programme, has joined DSM's Sustainability Advisory Board.

DSM repurchased 209,327 shares from 1 to 5 October 2018 at an average price of €90.13, finalizing program to repurchase 1,100,000 shares for a total of €98.9 million.

DSM repurchased 121,592 shares from 24 to 28 September 2018 at an average price of €91.88.

DSM repurchased 69,638 shares from 17 to 21 September 2018 at an average price of €91.24.

DSM repurchased 94,032 shares from 10 to 14 September 2018 at an average price of €88.38.

DSM recognized among the DJSI leaders for 15 years running and held the number one position in the sector eight times.

DSM repurchased 189,309 shares from 3 to 7 September 2018 at an average price of €88.16.

DSM repurchased 117,471 shares from 27 to 31 August 2018 at an average price of €91.17.

DSM repurchased 82,975 shares from 20 to 24 August 2018 at an average price of €89.58.

DSM named on Fortune Magazine’s ‘Change the World’ List for third consecutive year and again ranked number 1 globally in sustainability by Sustainalytics

DSM repurchased 215,656 shares from 13 to 17 August 2018 at an average price of €89.80.

DSM intends to repurchase 1,100,000 ordinary shares: 500,000 to cover commitments under share-based compensation plans and 600,000 to cover part of the interim dividend 2018.

Acquisition builds on partnership combining DSM’s unparalleled expertise in micronutrients with Mixfit technology.

Bain Capital intends to acquire DSM Sinochem Pharmaceuticals, a DSM and Sinochem Group 50/50 joint venture, with the transaction expected to be completed in the fourth quarter of 2018 subject to customary regulatory approvals and consultations.

DSM repurchased 324,894 shares from 15 to 20 June 2018 at an average price of €88.18, concluding program to repurchase 1,600,000 shares for a total of €136.7 million.

With its unique science-based competences, DSM is ideally positioned to capture the growth opportunities offered by the global megatrends and Sustainable Development Goals (SDGs), with a particular focus on Nutrition & Health, Climate & Energy and Resources & Circularity.

DSM repurchased 132,098 shares from 8 to 14 June 2018 at an average price of €89.07.

DSM repurchased 141,033 shares from 1 to 7 June 2018 at an average price of €88.22.

From 2018 all DSM's purchased electricity in the Netherlands will come from renewable sources, thanks to an agreement with Dutch energy supplier Eneco.

DSM repurchased 233,975 shares from 25 to 31 May 2018 at an average price of €86.30.

DSM repurchased 176,500 shares from 18 to 24 May 2018 at an average price of €88.02.

DSM and CVC Capital Partners indirectly own 35% and 65% respectively of the shares of Fibrant BV through Chemicalnvest joint venture.

DSM repurchased 91,500 shares from 14 to 17 May 2018 at an average price of €87.39.

DSM declares a dividend for the financial year 2017 of €1.85 per ordinary share.

DSM held its Annual General Meeting of Shareholders on 9 May 2018. Shareholders approved all resolutions on the agenda.

Royal DSM issues its full Q1 2018 results, which are in line with the preliminary figures for Q1 2018 previously announced on 12 April 2018.

DSM repurchased 88,350 shares from 6 to 12 April 2018 at an average price of €81.74.

Continued strong organic sales growth in underlying business estimated at 11%. Adjusted EBITDA growth of underlying business estimated at 7% despite significant FX headwind. Additional temporary vitamin price benefit estimated at €165m on Adjusted EBITDA. Overall very strong quarter with total Adjusted EBITDA up 55%.

DSM repurchased 87,000 shares from 3 to 5 April 2018 at an average price of €80.10.

DSM repurchased 188,000 shares from 23 to 29 March 2018 at an average price of €79.38.

DSM repurchased 136,650 shares from 19 to 22 March 2018 at an average price of €80.59.

Companies signed two long-term power purchase agreements (PPAs) that enabled construction of two windfarm projects.

DSM intends to repurchase 1,600,000 ordinary shares to cover commitments under share based compensation plans and and part of the final dividend 2017.

The 2017 Integrated Annual Report details the company's progress and performance over the year in terms of People, Planet and Profit.

DSM again reports an excellent year, as it significantly exceeded its Strategy 2018 targets for EBITDA, ROCE and organic sales growth.

Sale of Amyris Brasil Ltda to DSM and the establishment of a long-term manufacturing partnership for Amyris’s high-volume products finalized.

DSM expands its offering in gut health ingredients with probiotics, an attractive market segment in nutritional ingredients, growing an estimated 7% per year.

Call for framework conditions laying foundation for a pathway to limiting global temperature rise to well below 2° Celsius and allow them to actively contribute to the implementation of the Paris Agreement.

Report details how four major corporate renewable energy buyers came together to successfully aggregate demand and jointly sign multiple wind power PPAs in Europe.

DSM and Amyris enhance their strategic alliance through the sale of Amyris Brasil Ltda to DSM and the establishment of a long-term manufacturing partnership for Amyris’ high-volume products.

DSM repurchased 151,900 shares from 10 to 14 November 2017 at an average price of €75.63, concluding program to repurchase 1,600,000 shares for a total of €109.3 million.

DSM positioned to outpace its global target of 50% purchased electricity from renewable sources by 2025.

DSM and Haixing will be able to expand their global business of sustainable and innovative hydrocolloid solutions applied in food, beverage and personal care products to provide texture and stability.

DSM repurchased 243,624 shares from 3 to 9 November 2017 at an average price of €76.15.

Strong performance in Q3 2017, contributing to very good first nine months.

DSM repurchased 37,600 shares from 6 to 12 October 2017 at an average price of €69.54.

DSM repurchased 140,692 shares from 29 September to 5 October 2017 at an average price of €69.52.

DSM repurchased 163,310 shares from 22 to 28 September 2017 at an average price of €67.75.

EBITDA and ROCE outlook for 2017 confirmed. DSM aims to continue to deliver against its strategic targets in 2018. DSM brings forward its regular strategic review process for the period beyond 2018 and expects to share the conclusions before the summer of 2018.

DSM repurchased 117,424 shares from 15 to 21 September 2017 at an average price of €66.56.

Twilmij’s core values, customer portfolio and solutions are a perfect fit with DSM’s ambitions in the animal nutrition & health market.

DSM repurchased 128,851 shares from 8 to 14 September 2017 at an average price of €66.04.

DSM in 2nd place in Fortune Magazine’s 3rd annual Change the World list, which recognizes 56 companies that have had a positive social impact through activities that are part of their core business strategy.

DSM repurchased 142,315 shares from 1 to 7 September 2017 at an average price of €65.01.

DSM again named among worldwide leaders in the Materials industry group in the Dow Jones Sustainability World Index having been named among the global leaders for the past 14 years and holding the number one position in the sector seven times, including last year.

DSM repurchased 188,430 shares from 25 to 31 August 2017 at an average price of €64.01.

Thermo Fisher Scientific Inc. has completed the acquisition of Patheon N.V. (NYSE:PTHN), a company in which DSM held approximately 48.7 million ordinary shares.

DSM repurchased 185,837 shares from 18 to 24 August 2017 at an average price of €63.98.

DSM repurchased 100,017 shares from 14 to 17 August 2017 at an average price of €63.21.

DSM intends to repurchase 1,600,000 ordinary shares to cover commitments under management and personnel option plans and for part of the interim dividend 2017.

DSM maintained its positive momentum with a very strong first half-year performance with Q2 another very good quarter.

Judith Wiese will join DSM as Executive Vice President Group People & Organization on 1 October 2017.

DSM repurchased 261,898 shares from 7 to 13 July 2017 at an average price of €63.24, concluding program to repurchase 2,900,000 shares for a total of €187.2 million.

DSM repurchased 218,403 shares from 30 June to 6 July 2017 at an average price of €63.72.

DSM repurchased 182,175 shares from 23 to 29 June 2017 at an average price of €65.07.

DSM repurchased 122,307 shares from 16 to 22 June 2017 at an average price of €67.16.

DSM repurchased 123,435 shares from 9 to 15 June 2017 at an average price of €66.00.

Support from DSM and global partners to scale-up 100% renewable energy solution.

DSM repurchased 132,717 shares from 2 to 8 June 2017 at an average price of €65.73.

DSM repurchased 123,673 shares from 26 May to 1 June 2017 at an average price of €66.16.

DSM repurchased 123,847 shares from 19 to 25 May 2017 at an average price of €66.10.

DSM repurchased 139,447 shares from 12 to 18 May 2017 at an average price of €66.66.

Thermo Fisher will commence a tender offer to acquire all of the issued and outstanding shares of Patheon for $35.00 per ordinary share in cash.

DSM repurchased 128,958 shares from 5 to 11 May 2017 at an average price of €65.76.

DSM to make equity investment in Amyris and the companies to enter development cooperation focused on products for the health and nutrition markets.

DSM repurchased 114,048 shares from 28 April to 4 May 2017 at an average price of €66.44.

DSM declares a dividend for the financial year 2016 of €1.75 per ordinary share.

DSM held its Annual General Meeting of Shareholders on 3 May 2017. Shareholders approved all resolutions on the agenda.

DSM reports a very strong first quarter in 2017.

DSM repurchased 126,540 shares from 21 to 27 April 2017 at an average price of €65.81.

DSM repurchased 75,948 shares from 18 to 20 April 2017 at an average price of €65.02.

DSM repurchased 126,073 shares from 7 to 13 April 2017 at an average price of €65.16.

Finalists selected from ten best science and entrepreneurial team submissions.

DSM repurchased 134,338 shares from 31 March to 6 April 2017 at an average price of €64.04.

New state-of-the-art biotechnology facility will accelerate DSM’s biotechnology research and development capabilities for applications in food and nutrition, feed, fuel, pharma and bio-based materials.

DSM repurchased 235,605 shares from 24 to 30 March 2017 at an average price of €62.81.

DSM repurchased 308,025 shares from 17 to 23 March 2017 at an average price of €62.12.

DSM proposes re-appointment of Dimitri de Vreeze the Managing Board and appointment of John Ramsay and Frits van Paasschen to the Supervisory Board.

DSM repurchased 222,563 shares from 13 to 16 March 2017 at an average price of €62.92 for a total of €14.0 million.

DSM to repurchase 2,900,000 ordinary shares to cover commitments under management and personnel option plans and for part of final dividend 2016.

2016 Integrated Annual Report, in which DSM reports on its progress and performance over the year in terms of People, Planet and Profit, published on 3 March 2017.

Plant has achieved 70 gallon per ton conversion rate and POET-DSM Advanced Biofuels will now build an on-site enzyme manufacturing facility in Emmetsburg, Iowa, pending state and local approvals.

DSM reports a very good 2016 in which it achieved strong EBITDA and ROCE growth, well ahead of the mid-term targets set out in its Strategy 2018: Driving Profitable Growth.

DSM updates way its financial results are presented starting with Q4/full-year results for 2016, following recent changes to accounting and reporting guidelines in Europe.

Robin Chase, cofounder and former CEO of Zipcar, member of Boards of Veniam, World Resources Institute and Tucows and advisor to French National Digital Agency and USDOT’s Advisory Committee on Automated Transportation, joins DSM's Sustainability Advisory Board.

DSM repurchased 361,907 shares from 2 to 8 December 2016 at an average price of €56.21 and concluded the program to repurchase 1,700,000 shares.

DSM repurchased 215,424 of its own shares from 25 November to 1 December 2016 at an average price of €57.32.

DSM repurchased 248,036 shares from 18 to 24 November 2016 at an average price of €57.14.

DSM announces the departure of Managing Board and Executive Committee member Stephan B. Tanda as of 1 February 2017.

DSM repurchased 360,149 shares from 11 to 17 November 2016 at an average price of €56.21.

DSM reports another strong quarter in Q3 2016.

DSM repurchased 514,484 shares from 4 to 10 November 2016 at an average price of €56.17.

DSM intends to repurchase up to 1,700,000 ordinary shares in order to cover its commitments under management and personnel option plans.

DSM announces the successful launch of a €750 million bond, with a ten-year maturity due in 2026, at a coupon of 0.75%.

DSM has been named the worldwide leader in the Materials industry group in the Dow Jones Sustainability World Index 2016.

DSM reports a second consecutive strong quarter in 2016.

DSM announces the successful completion of its secondary offering of 4,761,905 ordinary shares in Patheon N.V. in connection with Patheon N.V.’s Initial Public Offering of ordinary shares.

DSM repurchased 83,073 shares from 15 to 21 July 2016 at an average price of €56.75 and concluded the program to repurchase 3,500,000 shares.

Patheon N.V., a company in which DSM holds approximately 53.5 million ordinary shares, has priced its Initial Public Offering at USD 21.00 per ordinary share.

DSM repurchased 107,432 shares from 8 to 14 July 2016 at an average price of €54.67.

Patheon N.V., a company in which DSM holds approximately 53.5 million ordinary shares, has today commenced an Initial Public Offering.

DSM repurchased 95,055 shares from 1 to 7 July 2016 at an average price of €52.09.

DSM repurchased 248,553 shares from 24 to 30 June 2016 at an average price of €50.64.

DSM repurchased 115,202 shares from 17 to 23 June 2016 at an average price of €53.57.

DSM repurchased 125,684 shares from 10 to 16 June 2016 at an average price of €53.20.

DSM intends to increase the running share repurchase program by an additional 300,000 shares to a total of 3,500,000 to cover the interim stock dividend 2016.

DSM repurchased 151,361 shares from 27 May to 2 June 2016 at an average price of €54.46.

DSM repurchased 152,420 shares from 20 to 26 May 2016 at an average price of €53.26

DSM repurchased 152,511 shares from 13 to 19 May 2016 at an average price of €52.54.

DSM repurchased 153,360 shares from 6 to 12 May 2016 at an average price of €52.27.

DSM repurchased 153,694 shares from 29 April to 5 May 2016 at an average price of €52.34.

DSM provides an update on the development of its Nutrition organization and several key positions to further support its growth plans.

DSM held its Annual General Meeting of Shareholders on 29 April 2016. Shareholders approved all resolutions on the agenda.

DSM repurchased 163,523 shares from 22 to 28 April 2016 at an average price of €53.25.

DSM declares a dividend for the financial year 2015 of €1.65 per ordinary share of €1.50 nominal value.

DSM reports a strong first quarter in 2016.

DSM repurchased 153,579 shares from 15 to 21 April 2016 at an average price of €52.05.

DSM repurchased 153,992 shares from 8 to 14 April 2016 at an average price of €50.01.

DSM repurchased 167,229 shares from 1 to 7 April 2016 at an average price of €47.8951.

DSM repurchased 93,033 shares from 29 to 31 March 2016 at an average price of €48.5712.

All members of the Executive Committee purchase ordinary shares in Royal DSM, expressing their confidence in the growth prospects of the company.

DSM repurchased 159,637 shares from 18 to 24 March 2016 at an average price of €48.28.

DSM repurchased 161,667 shares from 11 to 17 March 2016 at an average price of €48.06.

DSM repurchased 232,331 shares from 4 to 10 March 2016 at an average price of €47.13.

DSM repurchased 269,930 shares from 26 February to 3 March 2016 at an average price of €45.84.

DSM announces the publication of its 2015 Integrated Annual Report.

DSM repurchased 267,680 shares from 22 to 25 February 2016 at an average price of €43.94.

Ndidi Okonkwo Nwuneli, founder of LEAP Africa and co-founder of AACE Food Processing & Distribution Ltd and partner at Sahel Capital, an advisory and private equity firm, has joined DSM's Sustainability Advisory Board.

DSM to repurchase 3,200,000 ordinary shares to cover commitments under management and personnel option plans and as part of the final dividend 2015.

Q4 Group net sales up 6% to €1,926m and EBITDA up 3% to €261m.

At the Annual General Meeting of Shareholders the Supervisory Board will nominate Mr. Pradeep Pant for appointment as a member of DSM's Supervisory Board.

DSM and the United Nations World Food Programme sign agreement extending their existing partnership to combat hidden hunger and malnutrition in the developing world to 2018.

DSM and Syngenta R&D partnership to develop microbial-based agricultural solutions, including bio-controls, bio-pesticides and bio-stimulants.

After a period of transformation, DSM will focus on improving its financial results through organic growth, reducing costs and strict capital allocation.

Sales up 8%, driven by 7% organic growth in Nutrition and foreign exchange.

DSM awarded FD-Henri Sijthoff prize for the best annual report by a company listed on the AEX stock exchange in the Netherlands for its 2014 Integrated Annual Report.

DSM successfully issued a €500 million 1.375% bond due 2022.

DSM named among the worldwide leaders in the Materials industry group in the Dow Jones Sustainability World Index 2015.

Adjustments to organizational and operating model aim to create more agile, focused and cost efficient organization, with a stronger business and market focus and globally leveraged support functions.

Solid sales performance with a 12% increase to €1,965 million, supported by foreign exchange rates and 3% volume growth.

Partnership finalized for DSM’s activities in Polymer Intermediates (Caprolactam & Acrylonitrile) and Composite Resins with formation of ChemicaInvest B.V..

DSM repurchased 204,254 shares from 24 to 28 July 2015 at an average price of €52.44 and concluded the program to repurchase 2,300,000 shares.

DSM repurchased 184,648 shares from 17 to 23 July 2015 at an average price of €54.52.

DSM repurchased 74,088 shares from 10 to 16 July 2015 at an average price of €53.54.

DSM repurchased 190,870 shares from 3 to 9 July 2015 at an average price of €51.34.

DSM repurchased 362,143 shares from 26 June to 2 July 2015 at an average price of €53.03.

DSM repurchased 245,123 shares from 19 to 25 June 2015 at an average price of €53.87.

DSM begins debate on the contribution of science to society: www.sciencecanchangetheworld.org.

DSM repurchased 223,561 shares from 12 to 18 June 2015 at an average price of €52.87.

DSM repurchased 185,315 shares from 5 to 11 June 2015 at an average price of €53.36.

DSM repurchased 277,686 shares from 29 May to 4 June 2015 at an average price of €53.95.

DSM repurchased 128,219 shares from 22 to 28 May 2015 at an average price of €53.8102.

DSM repurchased 224,093 shares from 18 to 21 May 2015 at an average price of €53.18.

DSM intends repurchasing 2,300,000 ordinary shares in order to cover its commitments under management and personnel option plans.

DSM declares dividend for the financial year 2014 of €1.65 per ordinary share.

DSM held its Annual General Meeting of Shareholders on 30 April 2015. Shareholders approved all resolutions on the agenda.

Sales of €1,886 million, up 11%, including 2% organic sales growth.

DSM Synres produced solvent-borne alkyd and acrylic coating resins for the global coatings, adhesives and graphic arts markets.

Figures reflect reclassification of Polymer Intermediates cluster and DSM Composite Resins to discontinued operations. Corporate Activities are restated and also reflect the sale of DSM Synres.

DSM has successfully issued a €500 million 1.0% bond due 2025.

DSM finalizes acquisition of Aland, a Hong Kong-based company producing vitamin C in mainland China.

DSM proposes re-appointment of Stephan B. Tanda and announces departure of Stefan Doboczky as of 1 June 2015.

Partnership for DSM’s activities in Polymer Intermediates (Caprolactam and Acrylonitrile) and Composite Resins with formation of new company 65% owned by CVC and 35% by DSM.

Euroresins, a distributor of products to the composite resins industry, sold to Cathay Investments.

DSM announces publication of 2014 Integrated Annual Report.

Sales of €9,181 million, a 4% increase versus 2013. In line with market expectations, DSM reported EBITDA of €1,168 million compared to €1,261 million in 2013.

DSM has reached agreement with Cathay Investments for the sale of Euroresins and the transaction is expected to close in Q1 2015.

DSM has reached agreement with Standard Investment for the sale of DSM Synres and the transaction is expected to close in Q1 2015.

DSM provides investors with update on its strategic progress and current priorities at annual Capital Markets Day.

Third quarter 2014 EBITDA from continuing operations of €315 million compared to €293 million in Q2 2014 and €331 million in Q3 2013.

DSM named among the worldwide leaders in the Materials industry group in the Dow Jones Sustainability World Index 2014.

POET-DSM Advanced Biofuels proves its revolutionary technology that converts agricultural residue into renewable fuel at opening of its first commercial cellulosic ethanol plant.

DSM's second quarter 2014 EBITDA from continuing operations of €293 million compared to €332 million in Q2 2013, and €272 million in Q1 2014.

DSM reaches agreement to acquire Aland, a Hong Kong-based company producing vitamin C in mainland China.

Production of a few intermediates, mainly for Animal Nutrition & Health interrupted. Impact on customers expected to be minimal.

DSM repurchased 69,522 shares from 16 to 19 May 2014 at an average price of €51.67 and concluded the program to repurchase 5,000,000 shares.

DSM repurchased 176,832 shares from 9 to 15 May 2014 at an average price of €51.97.

DSM repurchased 294,921 shares from 2 to 8 May 2014 at an average price of €52.03.

DSM declares dividend for the financial year 2013 of €1.65 per ordinary share.

DSM held its Annual General Meeting of Shareholders on 7 May 2014. Shareholders approved all resolutions on the agenda.

DSM reports first quarter EBITDA from continuing operations of €272 million compared to €301 million in Q1 2013.

DSM repurchased 201,426 shares from 25 to 30 April 2014 at an average price of €51.49.

DSM repurchased 170,120 shares from 22 to 24 April 2014 at an average price of €50.42.

DSM repurchased 231,586 shares from 11 to 17 April 2014 at an average price of €49.15.

DSM repurchased 256,801 shares from 4 to 10 April 2014 at an average price of €50.17.

DSM in exclusive discussions with Aland that may or may not result in the acquisition of this China-based global producer of vitamin C.

DSM repurchased 149,321 shares from 28 March to 3 April 2014 at an average price of €50.05.

DSM repurchased 157,579 shares from 21 to 27 March 2014 at an average price of €48.46.

DSM repurchased 108,500 shares from 14 to 20 March 2014 at an average price of €46.51.

DSM repurchased 254,756 shares from 7 to 13 March 2014 at an average price of €47.40.

USD 2.65 billion transaction to create global CDMO leader successfully completed.

DSM to appoint Geraldine Matchett as Member of the Managing Board of Directors as of 1 August 2014 and as of 1 December 2014, she will become Chief Financial Officer.

DSM repurchased 428,636 shares from 27 February to 6 March 2014 at an average price of €46.54.

DSM issues €500 million 2.375% bond due 2024.

DSM intends to repurchase of 2,500,000 ordinary shares to cover commitments under management and personnel option plans.

For full year 2013 DSM delivered 18% higher EBITDA while facing challenging economic environment. In Q4 the company realized 30% higher EBITDA.

DSM repurchased 874,725 shares from 17 January 2014 up to and including 21 January 2014 at an average price of €51.85 and concludes first part of program to repurchase 4-5 million shares in total.

DSM delivered roughly 20% higher EBITDA for the full year 2013, in spite of the challenging economic environment and in Q4 realized an approximately 30% higher EBITDA.

DSM repurchased 245,742 shares from 10 to 16 January 2014 at an average price of €56.90.

DSM repurchased 112,588 shares from 6 to 9 January 2014 at an average price of €57.88.

DSM repurchased 154,586 shares from 13 to 19 December 2013 at an average price of €55.35.

Final Terms of the €300,000,000 1.75% Notes due 13 November 2019 adjusted to reflect investors have a put option in the event of a change of control.

DSM repurchased 185,761 shares from 6 to 12 December 2013 at an average price of €56.08.

DSM repurchased 164,545 shares from 29 November to 5 December 2013 at an average price of €57.17.

Award recognizes DSM's global corporate leadership in efforts to mitigate food insecurity, prevent hidden hunger and promote sustainable development in low-income countries.

DSM repurchased 198,288 shares from 22 to 28 November 2013 at an average price of €58.39.

DSM repurchased 346.038 shares from 15 to 21 November 2013 at an average price of €59.06.

Global CDMO company combines DSM Pharmaceutical Products and Patheon.

DSM repurchased 217,727 shares from 6 to 14 November 2013 at an average price of €58.05.

DSM successfully issues €300 million 1.75% bond due 2019.

DSM intends to repurchase 2,500,000 ordinary shares to cover commitments under management and personnel option plans.

Q3 EBITDA of €342 million compared to €270 million in Q3 2012. 27% improvement realized despite ongoing challenging macro-economic environment.

DSM acquires 19% equity interest in Yantai Andre Pectin Co. Ltd., a China based producer of texturing ingredients.

DSM providing review of strategic progress and update on its 2015 targets at its annual Capital Markets Day.

DSM once again amongst leaders in chemical industry sector in Dow Jones Sustainability World Index 2013.

DSM reports second quarter EBITDA of €345 million compared to €290 million in Q2 2012 and €311 million in Q1 2013.

DSM acquires Unitech Industries Limited, a New Zealand based producer of nutritional products for both human and animal markets.

Feike Sijbesma joins Global CEO Council (GCC) of the Chinese People’s Association for Friendship with Foreign Countries (CPAFFC).

DSM to help provide effective nutrition interventions to 50 million pregnant and lactating woman and children under two per year by 2020 as part of DSM’s endorsement of Global Nutrition for Growth Compact.

Working together to achieve lasting progress in global health and development by improving the nutritional status of mothers and children.

Agreement to acquire 19% equity interest in Yantai Andre Pectin Co. Ltd. (Andre Pectin), a China based producer of texturing ingredients.

DSM declares a dividend for the financial year 2012 of €1.50 per ordinary share of €1.50 nominal value.

DSM held its Annual General Meeting of Shareholders on 3 May 2013. Shareholders approved all resolutions on the agenda.

DSM reports first quarter EBITDA of €311 million compared to €306 million in Q1 2012 and €243 million in Q4 2012.

Strategic partnership with Rostekhnologii (Rostec) in fields of biotechnology and functional materials.

Partnership with Ministry of Health Care of the Republic of Tatarstan aims to modernize the Republic’s public health sector through fortified nutrition.

DSM acquires Tortuga, a nutritional supplements company with a focus on pasture raised beef and dairy cattle for a total enterprise value of about €440 million.

DSM proposes appointing Mr. Dimitri de Vreeze to the Managing Board effective 1 September 2013.

DSM sells its participation in DEXPlastomers, a 50/50 Joint Venture of DSM with affiliate of ExxonMobil Chemical, to Borealis.

DSM delivered growth across all clusters in 2012 excluding caprolactam. Nutrition represents more than 70% of total EBITDA and become high value, global business with attractive growth prospects across the full value chain.

Agreement extends existing partnership to 2015 to combat hidden hunger and malnutrition in the developing world.

Completing acquisition of Fortitech is another milestone in implementation of DSM’s Nutrition strategy.

Award recognizes DSM's integrated Triple P approach to creating a sustainable business and shared value with all stakeholders.

University of Maastricht confers honor on Feike Sijbesma because of way he embodies DSM’s core value, sustainability.

Acquisition enables DSM to become a global tier one dairy ingredients supplier.

DSM awarded Sustainable Supply Chain Award 2012 for its responsible way of managing its supply chain.

DSM receives three prestigious awards in the Netherlands for its 2011 Integrated Annual Report.

Agreement with Borealis AG reached for sale of DEXPlastomers V.o.F and DSM's LldPE Compact Solution Technology.

Definitive agreement to acquire Fortitech, Inc. (Fortitech) in an all cash transaction for a total enterprise value of $634 million.

DSM continues to generate good results mainly driven by Nutrition cluster and make good progress towards strategic goals with purchase of Tortuga and Cargill’s cultures and enzymes business.

DSM to acquire Cargill’s cultures and enzymes business in an all cash transaction for a total enterprise value of €85 million.

DSM updates financial community at its annual Capital Markets Days on progress made with its DSM in Motion: driving focused growth strategy.

Chris Goppelsroeder appointed President and CEO DSM Nutritional Products effective 1 January 2013.

DSM in exclusive discussions with Cargill which may, or may not result in DSM's acquisition of Cargill’s cultures and enzymes business.

DSM again among leaders in chemical industry sector in the Dow Jones Sustainability World Index 2012.

Definitive agreement to acquire Tortuga Companhia Zootécnica Agrária (Tortuga) in all cash transaction for total enterprise value of about €465 million.

Life Sciences cluster accounts for around 70% of Q2 EBITDA offsetting weakness caused by caprolactam in Materials Sciences. Other Materials Sciences businesses improve.

DSM acquires Ocean Nutrition Canada, leading global provider of fish-oil derived nutritional products to dietary supplement and food and beverage markets for a total enterprise value of C$540 million.

DSM completes acquisition of Kensey Nash for a total enterprise value of approximately $360 million.

Tender offer to purchase all outstanding shares of common stock of Kensey Nash Corporation at a price of $38.50 per share successful.

Expiration of mandatory waiting period under Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, for previously announced tender offer for all outstanding shares of common stock of Kensey Nash Corporation.

DSM qualified as supplier of enzymes for DONG Energy - Inbicon’s wheat straw to cellulosic ethanol process.

DSM commences previously announced tender offer for all outstanding shares of common stock of Kensey Nash at a price of $38.50 per share.

Definitive agreement with Clearwater Fine Foods and funds managed by Richardson Capital to acquire Ocean Nutrition Canada for a total enterprise value of C$540 million.

Annual General Meeting of Shareholders approves appointing Mrs. Victoria Haynes and Mrs. Eileen Kennedy as Supervisory Board members.

DSM declares a dividend for 2011 of €1.45 per ordinary share of €1.50 par value.

DSM held its Annual General Meeting of Shareholders on 11 May 2012. Shareholders approved all resolutions on the agenda.

In a challenging business environment, DSM continued to make good progress in Q1 and the robust results represent a positive start to 2012.

DSM will acquire all outstanding shares of common stock of Kensey Nash through a cash tender offer, followed by a merger with a subsidiary of DSM, for $38.50 in cash per share for total enterprise value of approximately $360 million.

Jos Op Heij new Senior Vice President Corporate Control and Accounting, Hans Vossen new VP Corporate Treasury & Dave Huizing new VP Investor Relations.

DSM acquires certain assets, licenses and other agreements in the area of food enzymes and oilseed processing from Verenium for a total consideration including transaction and related expenses of $37 million.

2011 was another strong year for DSM despite challenges of global economy, adverse currency movements and high raw material costs and increases dividend for second consecutive year.

Cees Los joins DSM as General Counsel and Director Legal Affairs as of 15 April 2012.

Joint Venture to commercially demonstrate and license cellulosic bio-ethanol, the next step in the development of biofuels, based on their proprietary and complementary technologies.

Q3 2011 EBITDA from continuing operations €339 million, 26% ahead of Q3 2010, outlook remains unchanged: 2011 is expected to be a strong year with further progress towards achieving 2013 targets.

DSM repurchased 502,990 shares from 27 October to 2 November 2011 at an average price of €37.33 and concluded the program to repurchase 4,000,000 shares.

DSM repurchased 471,588 shares from 20 to 26 October 2011 at an average price of €36.81.

TCG developed OtCM™ system to monitor compliance with drug therapy.

DSM repurchased 545,760 shares from 13 to 19 October 2011 at an average price of €37.15.

DSM repurchased 391,817 shares from 6 to 12 October 2011 at an average price of €35.51.

DSM Supervisory Board proposes appointing Mrs. Victoria Haynes and Mrs. Eileen Kennedy as Supervisory Board members.

DSM repurchased 519,526 shares from 29 September to 5 October 2011 at an average price of €32.42.

DSM acquires Shandong ICD High Performance Fiber Co. Ltd. (ICD), based in Laiwu, Shandong province, China.

DSM updates investment community on progress made with strategy marking the shift from an era of intensive portfolio transformation to a strategy for the coming years of maximizing sustainable and profitable growth of ‘the new DSM’.

DSM repurchased 523,199 shares from 22 to 28 September 2011 at an average price of €31.49.

Unsecured credit facility of €500 million is for a minumum term of 5 years and a maximum term of 7 years.

DSM repurchased 404,055 shares from 15 to 21 September 2011 at an average price of €32.52.

DSM repurchased 641,065 shares from 7 to 14 September 2011 at an average price of €31.84.

DSM Personalized Nutrition’s corporate wellness business will become part of Viocare’s operations.

DSM once again retained its number one position in the chemical industry sector in the Dow Jones Sustainability World Index.

DSM intends to repurchase 4,000,000 ordinary shares to cover commitments under management and personnel option plans.

Sinochem Group has taken a 50% equity interest in DSM Anti-Infectives for total cash consideration of €210 million on a cash and debt-free basis with 1 January 2011 as effective date.

Exchange ratio for the dividend in shares has been determined at 1 new ordinary share for every 72.338 existing ordinary shares.

Philip Eykerman will join DSM as Executive Vice President Corporate Strategy & Acquisitions.

Q2 EBITDA from continuing operations €339 million, above both Q2 2010 and Q1 2011.

DSM and Nutreco confirm they have decided to jointly explore the possibility to acquire Provimi.

DSM acquires interest in manufacturer of environmentally friendly UV-curable resins.

Ventures cover marketing and production of engineering plastics compounds in Russia.

Acquisition of Vitatene allows DSM to strengthen the natural carotenoids offerings of its nutrition business as consumer demand for natural products continues to grow.

Acquisition adds new yeast and enzyme technologies for second generation biofuels.

Exchange ratio for the dividend in shares has been determined at 1 new ordinary share for every 48.077 existing ordinary shares.

DSM repurchased 264,319 shares from 13 to 16 May 2011 at an average price of €46.56 and concluded the program to repurchase 5,000,000 shares.

DSM repurchased 502,059 shares from 6 to 12 May 2011 at an average price of €46.05.

Acquisition allows DSM to strengthen the natural carotenoids offerings of its nutrition business as consumer demand for natural products continues to grow.

Feike Sijbesma received award in recognition of his outstanding contribution to development and innovation in industrial biotechnology.

New chemical building block offers bio-based alternative.

DSM repurchased 601,953 shares from 29 April to 5 May 2011 at an average price of €45.78.

DSM completes sale of DSM Elastomers to LANXESS for €310 million on a cash and debt-free basis.

DSM has tendered its 4.95% stake in Danisco to DuPont.

DSM repurchased 435,987 shares from 26 to 28 April 2011 at an average price of €45.33.

DSM declares dividend for 2010 of €1.35 per ordinary share of €1.50 par value.

DSM held its Annual General Meeting of Shareholders on 28 April 2011. Shareholders approved all resolutions on the agenda.

Q1 EBITDA from continuing operations up 14% to €325 million.

DSM intends to appoint Mr. Atzo Nicolaï (1960), currently Member of the Dutch House of Representatives (“Tweede Kamer der Staten-Generaal”) with effect from 1 June 2011.

DSM repurchased 368,294 shares from 15 to 21 April 2011 at an average price of €42.70.

DSM repurchased 326,090 shares from 8 to 14 April 2011 at an average price of €43.53.

DSM repurchased 376,582 shares from 1 to 7 April 2011 at an average price of €43.97.

DSM will implement changes in the presentation of its financial results as from Q1 2011.

DSM repurchased 349,822 of its own shares from 25 to 31 March 2011 at an average price of €43.34.

DSM repurchased 331,532 shares from 18 to 24 March 2011 at an average price of €42.33.

DSM repurchased 479,895 shares from 11 to 17 March 2011 at an average price of €41.13.

DSM repurchased 499,687 shares from 4 to 10 March at an average price of € 43.49.

DSM repurchased 463,780 shares from 24 February to 3 March 2011 at an average price of €42.74.

Partnership with Kemrock Industries in India for the production of specialty composite resins in India.

Acquisition adds new growth platform for healthy and natural food ingredients, focused on Omega-3 DHA and Omega-6 ARA.

DSM successfully completes subsequent offering period to its all-cash tender offer.

Jinling DSM Resins Co., Ltd. (JDR) will invest approximately €50 million in a new production facility for composite resins in Nanjing, China.

Supervisory Board proposes appointing Mr. Stefan Doboczky to DSM's Managing Board with effect from 1 May 2011.

Full-year operating profit continuing operations up 74% to €752 million, dividend increase of 12.5% per ordinary share proposed.

Royal DSM N.V today introduces a new company brand: Bright Science. Brighter Living™. The new brand is symbolic of the transition to the ‘new’ DSM.

DSM intends to repurchase 5,000,000 ordinary shares to cover commitments under management and personnel option plans.

DSM Supervisory Board has appointed Rob Routs as its new Chairman.

Tender offer to purchase all outstanding shares of common stock of Martek Biosciences Corporation successful.

Counsel of the National Competition Commission approves acquisition.

DSM to acquire the majority shareholding in Shandong ICD High Performance Fibre Co Ltd. based in Laiwu, China.

DSM will use new P&L from the publication of the full year 2010 results onwards.

Waiting period for DSM's offer for all outstanding shares of Martek Biosciences Corporation at a price of $31.50 per share closes.

DSM and United States Agency for International Development (USAID) to collaborate and collectively work to meet the nutritional challenges presented in the developing world.

DSM Engineering Plastics to enter two joint ventures with KA.

DSM commences tender offer for all outstanding shares of common stock of Martek Biosciences Corporation at a price of $31.50 per share.

DSM holds a 4.95% stake in Danisco which has been acquired some years ago.